Injectable and Oral Immunotherapies Reduce Use of Asthma Medications
The Role of Immunotherapy and the Management of Asthma, a new evidence review from AHRQ’s Effective Health Care Program, explores the role of both injectable and oral immunotherapies for asthma treatment.
Researchers noted that standard treatment guidelines for immunotherapy do not yet include the use of sublingual therapy to treat asthma. Researchers also found that sublingual therapy improves asthma symptoms and the use of long-term control medications and may improve quality of life. Local and systemic allergic reactions are common, while life-threatening events are reported rarely for both interventions.
Select to access The Role of Immunotherapy and the Management of Asthma.
Page originally created April 2018